Here are the 10-K annual reports from BeOne Medicines Ltd. (ONC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ONC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONC filings page.
BeOne Medicines Ltd. reports a strong 2025 with rapid growth and first-time profitability driven by its global oncology franchise. The company generated approximately $5.3 billion in total global revenue in 2025, up about 40.2% year over year, and produced net income of $286.9 million.
Operations generated $1.1 billion of net cash from operating activities and free cash flow of $941.7 million, supporting a year-end balance of $4.5 billion in cash and cash equivalents and $1.0 billion of debt. Product revenue grew 39.8% from 2024.
Growth is led by oncology blockbusters BRUKINSA, a BTK inhibitor with about $3.9 billion in 2025 sales and approvals in over 75 markets, and PD‑1 antibody TEVIMBRA, which is approved in more than 50 markets and broadly listed on China’s NRDL. The company is building a “foundational” chronic lymphocytic leukemia franchise around BRUKINSA, BCL2 inhibitor sonrotoclax, and BTK degrader BGB‑16673, while advancing a deep solid-tumor pipeline and over 70 preclinical programs.